AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal
AtaiBeckley is in structured discussions with pharma companies and royalty investors about a potential partnership for its lead candidate, intranasal 5-MeO-DMT (BPL-003) for treatment-resistant depression (TRD), sources close to the company told Psychedelic Alpha. Here, we take a closer look...
External link. We are not responsible for the content.
Read more ↗More From Psychedelic Alpha
Pα+ Psychedelic Bulletin #221: Helus Reports Murky Phase 2a Results; AtaiBeckley Says R-MDMA Met Safety Goal in SAD, Details Phase 3 Design for 5-MeO-DMT in TRD; Psilocybin for Smoking Cessation Study Published
Policy Round-Up: State Momentum, Congressional Signals, and Colorado’s Data Build-Out • RAND Survey: Americans Divi...
Pα+ February 2026 Psychedelic Bill Roundup
A state-by-state and federal review of psychedelics-related bills introduced or advanced in February 2026, including ...
The State of the Psychedelic Industry & Open Questions (Video)
In the third video of a three-part series, Psychedelic Alpha’s Josh Hardman takes a look at some broader open questio...
Latest News
Out of This World: Why AI Belongs Beside the Therapist
Safar founder Sabba Nazhand watched the mental health system fail his mother, then himself. He argues AI's place is b...
An Amanita mushroom poisoning outbreak in California; A case report testing psilocybin for advanced Alzheimer’s disease
Plus: Scientists assess risk of psychedelic-induced mania; and the close of this season’s psychedelic legislation push
When Do Psychedelics Go Too Far?
Welcome to The Psychedelic Blog.
Do Psychedelics Actually Improve Athletic Performance?
Athletes say they feel stronger, calmer, and faster. Does the data back this up? [...] Read More... The post Do Psych...
Shroomski Melt
Shroomski Magazine drops their latest issue at their annual Summer Melt with cover art done by the one and only, Luke...
Psychedelic Policy Briefing: June 11, 2026
Six states are moving fast on psychedelic policy in 2026: Michigan fights over ibogaine research funding, Colorado si...